September 25, 2024 07:00 AM EDT
R&D

2sev­en­ty bio, Bris­tol My­ers stop late-stage Abec­ma study in mul­ti­ple myelo­ma due to re­cruit­ment chal­lenges

Katherine Lewin

News Reporter

2sev­en­ty bio and its part­ner Bris­tol My­ers Squibb said Wednes­day that they are dis­con­tin­u­ing en­roll­ment in the Phase 3 Kar­M­Ma-9 study in­ves­ti­gat­ing Abec­ma in pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Am­gen re­ports dual Phase 3 wins in atopic der­mati­tis and myas­the­nia gravis

Ital­ian gene ther­a­py start­up nabs $52M for rare ge­net­ic dis­ease that Mod­er­na is work­ing on

Mer­ck­'s LAG-3 plus Keytru­da com­bo fails Phase 3 in col­orec­tal can­cer

FDA OKs In­tra­Bio's drug less than a week af­ter rare dis­ease's first-ever ap­proval

No­vo Nordisk CEO skep­ti­cal of PBM promis­es in Sen­ate hear­ing on weight loss drug prices

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times